Dorzolamide Hydrochloride; Timolol Maleate

Drug Usage Statistics, United States, 2008 - 2018

Dorzolamide Hydrochloride; Timolol Maleate Summary for 2018

Top drug rank #249 ( 16)
Estimated number of prescriptions in the United States (2018) 1,950,346
Estimated number of patients in the United States (2018) 443,808
Average total drug cost (USD)  
Per prescription $65.06
Per day of therapy $1.31/day
Average out-of-pocket cost (USD)  
Per prescription $21.18
Per day of therapy $0.54/day

Total Prescriptions and Patients Per Year (2008 - 2018)

Rank of Top Drugs Over Time

"Rank" refers to the frequency that a given medication is prescribed within a calendar year compared to all other medications. A rank of "4" would indicate that the medication was the fourth most commonly prescribed medication.

Year Rank Change
2008 234  27
2009 203  31
2010 247  44
2011 348  101
2012 311  37
2013 262  49
Year Rank Change
2014 281  19
2015 233  48
2016 200  33
2017 233  33
2018 249  16

Drug Cost Over Time (2008 - 2018)

  • Cost Per Prescription Fill: Average cost per filled prescription regardless of how many days of therapy the prescription is filled for (e.g. 10 days, 30 days, 90 days, etc.)
  • Cost per Day of Therapy: The average cost per prescription fill divided by the days of therapy. For example, a 10-day antibiotic course costing $30 would be $3 per day. Similarly, a 30-day supply of an oral antihypetensive costing $30 would be $1 per day.

  • Total cost: The average total cost of the medication including the out-of-pocket cost (see below) plus the amount paid by other parties (Medicare, Medicaid, private insurance, Veterans Administration, TRICARE, other state/federal sources, Worker's compensation, and other miscellaneous sources)
  • Out-of-pocket cost: The average payment made by the patient which may include deductibles, coinsurance, copayments, or the cash price paid without insurance coverage.

Cost Per Prescription Fill (USD)

Cost Per Day of Therapy (USD/day)

NADAC (National Average Drug Acquisition Cost)

NADAC is the approximate cost of a medication that pharmacies (not patients) pay for a medication in the United States. Cost data is obtained via monthly surveys of community pharmacies. NADAC pricing is considered a more accurate alternative than average wholesale price (AWP). For more information, see NADAC (from or the NADAC data explorer.

NADAC prices vary by NDC (national drug code number), manufacturer, quanity of medication per bottle, and many other factors. The cost data displayed below represents the average pharmacy acquisition cost over the past 90 days.

Description Avg NADAC Price Pricing Unit

Distribution of Dispensed Dosage Forms (2018)

Dosage Form Strength % of Dispensed Products
Solution 22.3/6.8 mg/ml 100.0%

Distribution of Days Supplied (2018)

"Days supply" is defined as the number of days that a prescription should last. For example, a prescription of 60 tablets that is taken twice daily has a day supply of 30 days.

Related Drugs

Drug Name Total Prescriptions (2018)
Metoprolol 71,581,961
Carvedilol 22,737,639
Atenolol 18,644,885
Propranolol Hydrochloride 14,571,768
Timolol 4,312,018
Nebivolol Hydrochloride 2,955,158
Labetalol 2,297,672
Dorzolamide Hydrochloride; Timolol Maleate (this drug) 1,950,346
Bisoprolol Fumarate; Hydrochlorothiazide 1,556,623
Bisoprolol Fumarate 1,396,798
Dorzolamide Hydrochloride 1,158,075
Acetazolamide 761,295

Drug Synonyms

Drug synonyms are used during the sanitation and standardization process of "cleaning" the original data source (MEPS). Occassionally, brand names may be listed below that are no longer on the market or are very infrequently used.

Brand Name Synonyms
  • Cosopt
  • Cosopt PF
  • Dorzolamide Hydrochloride And Timolol Maleate
Generic Drug Synonyms and Salts
  • Dorzolamide Hydrochloride; Timolol Maleate; Brimonidine Tartrate
  • Dorzolamide Hydrochloride; Timolol Maleate; Latanoprost
  • Timolol Maleate; Dorzolamide Hydrochloride
  • Dorzolamide Hydrochloride; Timolol Maleate

FDA Approval Information

Established Pharmacologic Class (EPC): Carbonic Anhydrase Inhibitor, beta-Adrenergic Blocker
Initial FDA approval date: 4/7/1998
First FDA applicant: Rx
First dosage form: Solution/Drops (ophthalmic)

Prescription data source: Medical Expenditure Panel Survey (MEPS) 2008-2018. Agency for Healthcare Research and Quality (AHRQ), Rockville, MD. ClinCalc DrugStats Database version 21.2. Read more about the ClinCalc DrugStats database.

All ClinCalc DrugStats figures and graphs on this page are licensed under Creative Commons Attribution-ShareAlike 4.0 International (CC BY-SA 4.0).


Related Links

Follow Us!

New and Popular


Open Menu

Cite This Page

Show AMA citation

©2021 - ClinCalc LLC. All rights reserved.
Disclaimer - Privacy Policy - Contact Us
Updated Jul 3, 2021
Back to Top